[go: up one dir, main page]

CR8572A - Derivados de oxidiazolona como agonistas de la actividad de delta ppar - Google Patents

Derivados de oxidiazolona como agonistas de la actividad de delta ppar

Info

Publication number
CR8572A
CR8572A CR8572A CR8572A CR8572A CR 8572 A CR8572 A CR 8572A CR 8572 A CR8572 A CR 8572A CR 8572 A CR8572 A CR 8572A CR 8572 A CR8572 A CR 8572A
Authority
CR
Costa Rica
Prior art keywords
derivatives
activity
oxidiazolona
agonists
ppar
Prior art date
Application number
CR8572A
Other languages
English (en)
Inventor
Stefanie Keil
Wolfgang Wendler
Maike Glien
Jochen Goerlitzer
Karen Chandross
Daniel G Mcgarry
Jean Merril
Patrick Bernardelli
Baptiste Ronan
Corinne Terrier
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR8572A publication Critical patent/CR8572A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a oxadiazolonas y a sus sales fisiologicamente aceptables y derivados fisiologicamente funcionales que muestran activiadad agonista de PPAR-delta. Se describen compuestos de formula (I).
CR8572A 2004-04-01 2006-08-24 Derivados de oxidiazolona como agonistas de la actividad de delta ppar CR8572A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
CR8572A true CR8572A (es) 2007-12-04

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8572A CR8572A (es) 2004-04-01 2006-08-24 Derivados de oxidiazolona como agonistas de la actividad de delta ppar

Country Status (37)

Country Link
US (3) US20070179191A1 (es)
EP (3) EP1586573B1 (es)
JP (1) JP2007530612A (es)
KR (1) KR20060135857A (es)
CN (1) CN100582104C (es)
AR (1) AR050576A1 (es)
AT (1) ATE435225T1 (es)
AU (1) AU2005231916A1 (es)
BR (1) BRPI0509517A (es)
CA (1) CA2561627A1 (es)
CR (1) CR8572A (es)
CY (1) CY1109370T1 (es)
DE (2) DE602004004631D1 (es)
DK (1) DK1740583T3 (es)
DO (1) DOP2005000051A (es)
EC (1) ECSP066892A (es)
ES (1) ES2329484T3 (es)
GT (1) GT200500028A (es)
HR (1) HRP20090493T1 (es)
IL (1) IL178056A0 (es)
MA (1) MA28495B1 (es)
MY (1) MY142431A (es)
NO (1) NO20064981L (es)
PA (1) PA8628701A1 (es)
PE (1) PE20060323A1 (es)
PL (1) PL1740583T3 (es)
PT (1) PT1740583E (es)
RS (1) RS51186B (es)
RU (1) RU2374243C2 (es)
SI (1) SI1740583T1 (es)
SV (1) SV2006002071A (es)
TN (1) TNSN06317A1 (es)
TW (1) TW200602342A (es)
UA (1) UA84203C2 (es)
UY (1) UY28837A1 (es)
WO (1) WO2005097786A1 (es)
ZA (1) ZA200606870B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
BRPI0616477A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de 2-amintiazóis e 2-amino-oxazóis, processos para a sua preparação e seus usos
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CN101273036A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
AU2007292874B2 (en) 2006-09-08 2013-11-21 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
AU2009256982A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2288607B1 (en) 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2009149819A1 (en) * 2008-06-09 2009-12-17 Sanofi-Aventis Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2349285B1 (en) 2008-10-10 2016-03-23 Dara Biosciences, Inc. Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain
EP3135672B9 (en) * 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
ES2439801T3 (es) * 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
EP2463279B1 (en) * 2009-08-05 2014-02-12 Daiichi Sankyo Company, Limited 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW222626B (es) * 1991-07-22 1994-04-21 Pfizer
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ, インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
ATE245636T1 (de) 1999-07-29 2003-08-15 Lilly Co Eli Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PT1237855E (pt) 1999-12-03 2004-06-30 Astrazeneca Ab Forma cristalina do acido (s)-2-etoxi-3-¬4-(2-{4-metanosulfoniloxifenil}etoxi)fenil|propanoico
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CA2400226C (en) 2000-03-31 2007-01-02 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1615900A1 (en) 2003-04-01 2006-01-18 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
CN101273036A (zh) * 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途

Also Published As

Publication number Publication date
PE20060323A1 (es) 2006-03-31
CN100582104C (zh) 2010-01-20
SV2006002071A (es) 2006-01-30
US20080262052A1 (en) 2008-10-23
DE602005015204D1 (de) 2009-08-13
US7709509B2 (en) 2010-05-04
PA8628701A1 (es) 2006-11-25
TW200602342A (en) 2006-01-16
HK1100408A1 (zh) 2007-09-21
AU2005231916A1 (en) 2005-10-20
PL1740583T3 (pl) 2009-12-31
US20070179191A1 (en) 2007-08-02
EP1586573B1 (en) 2007-02-07
ES2329484T3 (es) 2009-11-26
KR20060135857A (ko) 2006-12-29
EP1740583B1 (en) 2009-07-01
PT1740583E (pt) 2009-09-16
DK1740583T3 (da) 2009-10-19
EP2083006A1 (en) 2009-07-29
AR050576A1 (es) 2006-11-08
RU2006138498A (ru) 2008-05-10
MY142431A (en) 2010-11-30
CY1109370T1 (el) 2014-07-02
CA2561627A1 (en) 2005-10-20
IL178056A0 (en) 2006-12-31
EP1586573A1 (en) 2005-10-19
WO2005097786A1 (en) 2005-10-20
RU2374243C2 (ru) 2009-11-27
UY28837A1 (es) 2005-10-31
EP1740583A1 (en) 2007-01-10
HRP20090493T1 (hr) 2009-10-31
TNSN06317A1 (en) 2007-12-03
ZA200606870B (en) 2008-04-30
BRPI0509517A (pt) 2007-09-11
NO20064981L (no) 2006-12-28
CN1938300A (zh) 2007-03-28
RS51186B (sr) 2010-10-31
ATE435225T1 (de) 2009-07-15
UA84203C2 (en) 2008-09-25
GT200500028A (es) 2006-06-09
ECSP066892A (es) 2006-11-24
US20080255212A1 (en) 2008-10-16
SI1740583T1 (sl) 2009-12-31
JP2007530612A (ja) 2007-11-01
DOP2005000051A (es) 2005-12-15
MA28495B1 (fr) 2007-03-01
DE602004004631D1 (de) 2007-03-22

Similar Documents

Publication Publication Date Title
CR8572A (es) Derivados de oxidiazolona como agonistas de la actividad de delta ppar
CR10778A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiaxol-5-ona, procedimientos para su preparacion y su uso como agentes farmaceuticos
CR9784A (es) Derivados de fenil-[-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparacion y su uso como productos farmaceuticos
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
CR9851A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR10662A (es) Compuestos de metilpiridopirimidinona
UY30600A1 (es) Compuestos novedosos
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
NI200800217A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos.
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
NI201000059A (es) Inhibidores de la cinasa c-fms.
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
HN2004000544A (es) Nuevos derivados de quinolinas
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CR9785A (es) Phenyl-and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico

Legal Events

Date Code Title Description
FC Refusal